890 related articles for article (PubMed ID: 26717940)
21. Clinically significant genomic alterations in the Chinese and Western patients with intrahepatic cholangiocarcinoma.
Xu S; Guo Y; Zeng Y; Song Z; Zhu X; Fan N; Zhang Z; Ren G; Zang Y; Rao W
BMC Cancer; 2021 Feb; 21(1):152. PubMed ID: 33579226
[TBL] [Abstract][Full Text] [Related]
22. Patterns and prognostic significance of lymph node dissection for surgical treatment of perihilar and intrahepatic cholangiocarcinoma.
Guglielmi A; Ruzzenente A; Campagnaro T; Valdegamberi A; Bagante F; Bertuzzo F; Conci S; Iacono C
J Gastrointest Surg; 2013 Nov; 17(11):1917-28. PubMed ID: 24048613
[TBL] [Abstract][Full Text] [Related]
23. Enhancer of zeste homolog 2 (EZH2) promotes progression of cholangiocarcinoma cells by regulating cell cycle and apoptosis.
Nakagawa S; Okabe H; Sakamoto Y; Hayashi H; Hashimoto D; Yokoyama N; Sakamoto K; Kuroki H; Mima K; Nitta H; Imai K; Chikamoto A; Watanabe M; Beppu T; Baba H
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S667-75. PubMed ID: 23887863
[TBL] [Abstract][Full Text] [Related]
24. Epithelial cell adhesion molecule is a prognosis marker for intrahepatic cholangiocarcinoma.
Sulpice L; Rayar M; Turlin B; Boucher E; Bellaud P; Desille M; Meunier B; Clément B; Boudjema K; Coulouarn C
J Surg Res; 2014 Nov; 192(1):117-23. PubMed ID: 24909871
[TBL] [Abstract][Full Text] [Related]
25. Diagnostic and Prognostic Role of 18-FDG PET/CT in the Management of Resectable Biliary Tract Cancer.
Ma KW; Cheung TT; She WH; Chok KSH; Chan ACY; Dai WC; Chiu WH; Lo CM
World J Surg; 2018 Mar; 42(3):823-834. PubMed ID: 28905105
[TBL] [Abstract][Full Text] [Related]
26. Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma.
Joseph NM; Tsokos CG; Umetsu SE; Shain AH; Kelley RK; Onodera C; Bowman S; Talevich E; Ferrell LD; Kakar S; Krings G
J Pathol; 2019 Jun; 248(2):164-178. PubMed ID: 30690729
[TBL] [Abstract][Full Text] [Related]
27. New routes to targeted therapy of intrahepatic cholangiocarcinomas revealed by next-generation sequencing.
Ross JS; Wang K; Gay L; Al-Rohil R; Rand JV; Jones DM; Lee HJ; Sheehan CE; Otto GA; Palmer G; Yelensky R; Lipson D; Morosini D; Hawryluk M; Catenacci DV; Miller VA; Churi C; Ali S; Stephens PJ
Oncologist; 2014 Mar; 19(3):235-42. PubMed ID: 24563076
[TBL] [Abstract][Full Text] [Related]
28. Influence of hepatic resection margin on recurrence and survival in intrahepatic cholangiocarcinoma.
Tamandl D; Herberger B; Gruenberger B; Puhalla H; Klinger M; Gruenberger T
Ann Surg Oncol; 2008 Oct; 15(10):2787-94. PubMed ID: 18685896
[TBL] [Abstract][Full Text] [Related]
29. Significance of HMGA2 expression as independent poor prognostic marker in perihilar and distal cholangiocarcinoma resected with curative intent.
Takahashi T; Kawaji H; Murakawa Y; Hayashizaki Y; Murakami T; Yabushita Y; Homma Y; Kumamoto T; Matsuyama R; Endo I
Eur J Surg Oncol; 2021 Feb; 47(2):394-400. PubMed ID: 32878723
[TBL] [Abstract][Full Text] [Related]
30. Comprehensive analysis of genomic mutation signature and tumor mutation burden for prognosis of intrahepatic cholangiocarcinoma.
Zhang R; Li Q; Fu J; Jin Z; Su J; Zhang J; Chen C; Geng Z; Zhang D
BMC Cancer; 2021 Feb; 21(1):112. PubMed ID: 33535978
[TBL] [Abstract][Full Text] [Related]
31. A novel three‑miRNA signature predicts survival in cholangiocarcinoma based on RNA‑Seq data.
Cao J; Sun L; Li J; Zhou C; Cheng L; Chen K; Yan B; Qian W; Ma Q; Duan W
Oncol Rep; 2018 Sep; 40(3):1422-1434. PubMed ID: 29956786
[TBL] [Abstract][Full Text] [Related]
32. Prognosis and treatment of bile duct carcinoma.
Chung C; Bautista N; O'Connell TX
Am Surg; 1998 Oct; 64(10):921-5. PubMed ID: 9764692
[TBL] [Abstract][Full Text] [Related]
33. The impact of surgical treatment and poor prognostic factors for patients with intrahepatic cholangiocarcinoma: retrospective analysis of 60 patients.
Yamashita Y; Taketomi A; Morita K; Fukuhara T; Ueda S; Sanefuji K; Iguchi T; Kayashima H; Sugimachi K; Maehara Y
Anticancer Res; 2008; 28(4C):2353-9. PubMed ID: 18751418
[TBL] [Abstract][Full Text] [Related]
34. Surgery of extrahepatic bile duct cancer - current evidence and recommendations.
Nikov A; Gürlich R
Rozhl Chir; 2022; 101(9):416-420. PubMed ID: 36257799
[TBL] [Abstract][Full Text] [Related]
35. Gamma-synuclein is a novel prognostic marker that promotes tumor cell migration in biliary tract carcinoma.
Takemura Y; Ojima H; Oshima G; Shinoda M; Hasegawa Y; Kitago M; Yagi H; Abe Y; Hori S; Fujii-Nishimura Y; Kubota N; Masuda Y; Hibi T; Sakamoto M; Kitagawa Y
Cancer Med; 2021 Aug; 10(16):5599-5613. PubMed ID: 34245137
[TBL] [Abstract][Full Text] [Related]
36. Intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma: a Western experience.
Portolani N; Baiocchi GL; Coniglio A; Piardi T; Grazioli L; Benetti A; Ferrari Bravo A; Giulini SM
Ann Surg Oncol; 2008 Jul; 15(7):1880-90. PubMed ID: 18443881
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcome and prognostic factors of intrahepatic cholangiocarcinoma.
Li SQ; Liang LJ; Hua YP; Peng BG; He Q; Lu MD; Chen D
Chin Med J (Engl); 2009 Oct; 122(19):2286-91. PubMed ID: 20079127
[TBL] [Abstract][Full Text] [Related]
38. High Beclin-1 and ARID1A expression corelates with poor survival and high recurrence in intrahepatic cholangiocarcinoma: a histopathological retrospective study.
Bi C; Liu M; Rong W; Wu F; Zhang Y; Lin S; Liu Y; Wu J; Wang L
BMC Cancer; 2019 Mar; 19(1):213. PubMed ID: 30849962
[TBL] [Abstract][Full Text] [Related]
39. Surgical treatment of mass-forming intrahepatic cholangiocarcinoma: an 11-year Western single-center experience in 107 patients.
Yedibela S; Demir R; Zhang W; Meyer T; Hohenberger W; Schönleben F
Ann Surg Oncol; 2009 Feb; 16(2):404-12. PubMed ID: 19037702
[TBL] [Abstract][Full Text] [Related]
40. SOX4 is associated with poor prognosis in cholangiocarcinoma.
Wang W; Zhang J; Zhan X; Lin T; Yang M; Hu J; Han B; Hu S
Biochem Biophys Res Commun; 2014 Sep; 452(3):614-21. PubMed ID: 25181339
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
